Ellen McErlean

4.0k total citations · 2 hit papers
29 papers, 2.1k citations indexed

About

Ellen McErlean is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ellen McErlean has authored 29 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 17 papers in Surgery and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ellen McErlean's work include Lipoproteins and Cardiovascular Health (9 papers), Acute Myocardial Infarction Research (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Ellen McErlean is often cited by papers focused on Lipoproteins and Cardiovascular Health (9 papers), Acute Myocardial Infarction Research (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Ellen McErlean collaborates with scholars based in United States, Australia and France. Ellen McErlean's co-authors include Steven E. Nissen, Frederick Van Lente, Eric J. Topol, Vijay Nambi, Marlene Goormastic, Marie‐Luise Brennan, Ronnier J. Aviles, Stanley L. Hazen, Marc S. Penn and Michael Pepoy and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Ellen McErlean

28 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Value of Myeloperoxidase in Patients with Chest Pain

2003 796 citations Marie‐Luise Brennan, Marc S. Penn et al. New England Journal of Medicine profile →
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

2022 183 citations Milind Y. Desai, Anjali Owens et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen McErlean United States	16	919	712	465	417	299	29	2.1k
Pia Lundman Sweden	28	912 1.0×	826 1.2×	290 0.6×	770 1.8×	484 1.6×	70	2.5k
Danish Saleheen Pakistan	22	782 0.9×	796 1.1×	297 0.6×	561 1.3×	270 0.9×	45	2.4k
Tomonori Itoh Japan	21	755 0.8×	574 0.8×	267 0.6×	217 0.5×	171 0.6×	101	2.0k
Miguel Ángel Hernández-Presa Spain	16	713 0.8×	802 1.1×	657 1.4×	337 0.8×	329 1.1×	26	2.4k
Eric J. Stanek United States	19	609 0.7×	724 1.0×	340 0.7×	477 1.1×	113 0.4×	58	2.1k
Marios Margaritis United Kingdom	18	887 1.0×	604 0.8×	271 0.6×	125 0.3×	331 1.1×	33	1.9k
Jingfeng Wang China	27	688 0.7×	421 0.6×	210 0.5×	338 0.8×	270 0.9×	129	2.2k
Jürgen Meyer Germany	20	747 0.8×	697 1.0×	539 1.2×	190 0.5×	502 1.7×	32	2.6k
Włodzimierz J. Musiał Poland	22	877 1.0×	434 0.6×	248 0.5×	146 0.4×	210 0.7×	146	2.0k
Andrea Baragetti Italy	27	417 0.5×	538 0.8×	519 1.1×	318 0.8×	444 1.5×	85	1.9k

Countries citing papers authored by Ellen McErlean

Since Specialization

Citations

This map shows the geographic impact of Ellen McErlean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen McErlean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen McErlean more than expected).

Fields of papers citing papers by Ellen McErlean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen McErlean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen McErlean. The network helps show where Ellen McErlean may publish in the future.

Co-authorship network of co-authors of Ellen McErlean

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen McErlean. A scholar is included among the top collaborators of Ellen McErlean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen McErlean. Ellen McErlean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Milind Y., Anjali Owens, Jeffrey B. Geske, et al.. (2022). Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation. 147(11). 850–863. 53 indexed citations

Desai, Milind Y., Anjali Owens, Jeffrey B. Geske, et al.. (2022). Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. Journal of the American College of Cardiology. 80(2). 95–108. 183 indexed citations breakdown →

Laffin, Luke J., Dennis Bruemmer, Danielle M. Brennan, et al.. (2022). Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. Journal of the American College of Cardiology. 81(1). 1–12. 37 indexed citations

Desai, Milind Y., Kathy Wolski, Anjali Owens, et al.. (2021). Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. American Heart Journal. 239. 80–89. 38 indexed citations

Menon, Venu, Anirudh Kumar, Divyang Patel, et al.. (2020). Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Research & Care. 8(1). e000943–e000943. 19 indexed citations

Riesmeyer, Jeffrey, Giacomo Ruotolo, Govinda J. Weerakkody, et al.. (2018). Abstract 14025: Evacetrapib Alone or in Combination With Different Statin Doses Results in Differential Effect on Lipoproteins and MACE Rates: The ACCELERATE Trial. Circulation. 1 indexed citations

Nissen, Steven E., Sreekumar Pillai, Stephen J. Nicholls, et al.. (2018). ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. JAMA Cardiology. 3(5). 401–401. 27 indexed citations

Ruotolo, Giacomo, Michael Lincoff, Venu Menon, et al.. (2017). Abstract 17400: Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2 indexed citations

Nicholls, Stephen J., A. Michael Lincoff, Philip J. Barter, et al.. (2015). Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal. 170(6). 1061–1069. 67 indexed citations

10.

Nicholls, Stephen J., H. Bryan Brewer, John J.P. Kastelein, et al.. (2011). Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol. JAMA. 306(19). 2099–109. 299 indexed citations

11.

Bhatt, Deepak L., Derek P. Chew, Cindy L. Grines, et al.. (2007). Peroxisome proliferator–activated receptor γ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study. American Heart Journal. 154(1). 137–143. 30 indexed citations

12.

Borgman, Marilyn & Ellen McErlean. (2006). What Is the Metabolic Syndrome?. The Journal of Cardiovascular Nursing. 21(4). 285–290. 14 indexed citations

13.

Tang, W.H. Wilson, Steven R. Steinhubl, Frederick Van Lente, et al.. (2006). Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro–B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. American Heart Journal. 153(1). 36–41. 11 indexed citations

14.

Brennan, Marie‐Luise, Marc S. Penn, Frederick Van Lente, et al.. (2003). Prognostic Value of Myeloperoxidase in Patients with Chest Pain. New England Journal of Medicine. 349(17). 1595–1604. 796 indexed citations breakdown →

15.

Meldon, Stephen W., et al.. (2003). Troponin t in elders with suspected acute coronary syndromes. The American Journal of Emergency Medicine. 21(4). 293–297. 9 indexed citations

16.

Schoenhagen, Paul, Ellen McErlean, & Steven E. Nissen. (2000). The Vulnerable Coronary Plaque. The Journal of Cardiovascular Nursing. 15(1). 1–12. 9 indexed citations

17.

McErlean, Ellen, et al.. (2000). Comparison of troponin T versus creatine kinase-MB in suspected acute coronary syndromes. The American Journal of Cardiology. 85(4). 421–426. 33 indexed citations

18.

Kim, Kyoung‐Ah, D K Moser, Bonnie J. Garvin, et al.. (2000). Differences between men and women in anxiety early after acute myocardial infarction. American Journal of Critical Care. 9(4). 245–253. 47 indexed citations

19.

Lente, Frederick Van, et al.. (1999). Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. Journal of the American College of Cardiology. 33(2). 471–478. 85 indexed citations

20.

McErlean, Ellen. (1999). Thrombolytic Therapy versus Primary Angioplasty in the Treatment of Acute Myocardial Infarction. The Journal of Cardiovascular Nursing. 13(3). 46–59. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact